Executive Board of the Fondazione "Allineare Sanità e Salute", 20122 Milan, Italy.
Int J Environ Res Public Health. 2019 Nov 7;16(22):4347. doi: 10.3390/ijerph16224347.
Pregnant women are increasingly considered a priority group for influenza vaccination, but the evidence in favor relies mainly on observational studies, subject to the "healthy-vaccinee bias". Propensity score methods-sometimes applied-reduce but cannot eliminate residual confounding. Meta-analyses of observational studies show relative risks far from the thresholds that would confirm the efficacy of universal vaccination for pregnant women without needing randomized controlled trials (RCTs). Critical articles have shown that in the four RCTs investigating the outcomes of this vaccination, there was a tendency towards higher offspring mortality. In the largest RCT, there was a significant excess of presumed/serious neonatal infections, and also significantly more serious adverse events. Many widely acknowledged observational results (about hormone replacing therapy, vitamin D, omega-3 fatty acids, etc.) were confuted by RCTs. Therefore the international drive to consider this vaccination a "standard of care" is not justified yet. Moreover, there is the risk of precluding further independent RCTs for "ethical considerations", so as "to not deny the benefits of influenza vaccinations to pregnant women of a control group". Instead, before promoting national campaigns for universal vaccination in pregnancy, further large, independent, and reassuring RCTs are needed, even braving challenging a current paradigm. Until then, influenza vaccination should be offered to pregnant women only once open information is available about the safety uncertainties, to allow truly informed choices, and promoting also other protective behaviors.
孕妇越来越被视为流感疫苗接种的优先群体,但支持这一观点的证据主要来自观察性研究,容易受到“健康接种者偏差”的影响。倾向评分方法(有时会应用)可以减轻,但不能消除残余混杂。对观察性研究的荟萃分析显示,相对风险远低于确定对孕妇进行普遍接种有效性的阈值,而无需进行随机对照试验(RCT)。重要文章表明,在四项针对这种疫苗接种结局的 RCT 中,存在较高的后代死亡率趋势。在最大的 RCT 中,疑似/严重新生儿感染明显增多,严重不良事件也明显增多。许多被广泛认可的观察性结果(关于激素替代疗法、维生素 D、ω-3 脂肪酸等)都被 RCT 推翻了。因此,国际上认为将这种疫苗接种作为“标准护理”的做法还没有得到证实。此外,由于“出于伦理考虑”,有可能排除进一步的独立 RCT,以“不剥夺对照组孕妇流感疫苗接种的好处”。相反,在推广全国范围内在妊娠期间普遍接种疫苗之前,需要进行进一步的大型、独立且令人安心的 RCT,甚至需要勇敢地挑战当前的范式。在那之前,只有在关于安全性不确定性的公开信息可用的情况下,才能向孕妇提供流感疫苗接种,以允许真正知情的选择,并促进其他保护性行为。